1829 related articles for article (PubMed ID: 19607961)
1. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
Patel S; Hillard CJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):304-11. PubMed ID: 16569753
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress.
Bortolato M; Mangieri RA; Fu J; Kim JH; Arguello O; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
Biol Psychiatry; 2007 Nov; 62(10):1103-10. PubMed ID: 17511970
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
Fezza F; De Simone C; Amadio D; Maccarrone M
Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
[TBL] [Abstract][Full Text] [Related]
5. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
6. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition.
Rossi S; De Chiara V; Musella A; Sacchetti L; Cantarella C; Castelli M; Cavasinni F; Motta C; Studer V; Bernardi G; Cravatt BF; Maccarrone M; Usiello A; Centonze D
Mol Pharmacol; 2010 Aug; 78(2):260-8. PubMed ID: 20424126
[TBL] [Abstract][Full Text] [Related]
7. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
8. Activation of endocannabinoid transmission induces antidepressant-like effects in rats.
Adamczyk P; Gołda A; McCreary AC; Filip M; Przegaliński E
J Physiol Pharmacol; 2008 Jun; 59(2):217-28. PubMed ID: 18622041
[TBL] [Abstract][Full Text] [Related]
9. Cannabis and psychiatric disorders: it is not only addiction.
Leweke FM; Koethe D
Addict Biol; 2008 Jun; 13(2):264-75. PubMed ID: 18482435
[TBL] [Abstract][Full Text] [Related]
10. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.
Hayase T
BMC Neurosci; 2007 Sep; 8():76. PubMed ID: 17877812
[TBL] [Abstract][Full Text] [Related]
11. The role of endocannabinoids in the hypothalamic regulation of visceral function.
Wenger T; Moldrich G
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):301-7. PubMed ID: 12052044
[TBL] [Abstract][Full Text] [Related]
12. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.
Basavarajappa BS; Hungund BL
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):287-99. PubMed ID: 12052043
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoid system and stress and anxiety responses.
Viveros MP; Marco EM; File SE
Pharmacol Biochem Behav; 2005 Jun; 81(2):331-42. PubMed ID: 15927244
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid system and mood disorders: priming a target for new therapies.
Micale V; Di Marzo V; Sulcova A; Wotjak CT; Drago F
Pharmacol Ther; 2013 Apr; 138(1):18-37. PubMed ID: 23261685
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Jhaveri MD; Richardson D; Robinson I; Garle MJ; Patel A; Sun Y; Sagar DR; Bennett AJ; Alexander SP; Kendall DA; Barrett DA; Chapman V
Neuropharmacology; 2008 Jul; 55(1):85-93. PubMed ID: 18534634
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications.
Quistad GB; Sparks SE; Segall Y; Nomura DK; Casida JE
Toxicol Appl Pharmacol; 2002 Feb; 179(1):57-63. PubMed ID: 11884237
[TBL] [Abstract][Full Text] [Related]
17. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
Ligresti A; Petrosino S; Di Marzo V
Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
[TBL] [Abstract][Full Text] [Related]
18. Neurobiology and systems physiology of the endocannabinoid system.
Wegener N; Koch M
Pharmacopsychiatry; 2009 May; 42 Suppl 1():S79-86. PubMed ID: 19434559
[TBL] [Abstract][Full Text] [Related]
19. Uptake blockade of endocannabinoids in the NTS modulates baroreflex-evoked sympathoinhibition.
Brozoski DT; Dean C; Hopp FA; Seagard JL
Brain Res; 2005 Oct; 1059(2):197-202. PubMed ID: 16154548
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors and their ligands.
Pertwee RG; Ross RA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
